文献速递类风湿关节炎

类风湿关节炎中TNF抑制剂应答的预测因素:随机对照试验的个体患者数据汇总分析

Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials.
PubMed 文献 · RMD Open · 2021-01-01

该研究汇总29项随机对照试验的11617例类风湿关节炎患者个体数据,评估基线特征与TNF抑制剂应答的关系。至6个月时,肥胖患者EULAR无应答率显著更高(OR 0.52 vs 非肥胖者0.36,p=0.01)。多变量模型显示,病程每增加1年,最终DAS28(CRP)降低0.02(p<0.001);基线DAS28(CRP)>5.1者降低0.21(p<0.001)。

要点

  • 肥胖类风湿关节炎患者使用TNF抑制剂至6个月时EULAR无应答率显著高于非肥胖者。
  • 病程较长与TNF抑制剂治疗后DAS28(CRP)降幅更大相关。
  • 基线高疾病活动度(DAS28(CRP)>5.1)与TNF抑制剂治疗后DAS28(CRP)降幅更大相关。

核心结论

  • 在类风湿关节炎中,对TNF抑制剂应答更好的患者是非肥胖者、病程较长者和初始疾病活动度较高者。

研究设计与样本

  • 汇总29项评估TNF抑制剂与安慰剂或常规治疗疗效的随机对照试验的个体患者数据。
  • 按基线特征(吸烟状态、体力活动、性别、年龄、体重指数、自身抗体谱、病程、DAS28(CRP)>5.1定义的高初始疾病活动度)进行亚组分析。
  • 主要终点为基线至6个月DAS28(CRP)变化在治疗组间的差异;次要终点为至6个月最终DAS28(CRP)及EULAR应答标准的组间差异。
  • 各随机对照试验数据采用Mantel-Haenszel法以随机效应模型汇总,并在两个数据共享平台分别进行线性元回归以支持结果。

主要发现

  • 共分析来自29项随机对照试验的11617例患者个体数据。
  • 至6个月,肥胖患者EULAR无应答率显著高于非肥胖者(OR 0.52 vs 0.36,p=0.01)。
  • 对7457例患者的多变量回归模型显示,接受TNF抑制剂治疗者病程每增加1年,最终DAS28(CRP)降低0.02(p<0.001)。
  • 基线DAS28(CRP)>5.1者最终DAS28(CRP)降低0.21(p<0.001)。

关键数值与推荐

  • 肥胖患者EULAR无应答OR 0.52 vs 非肥胖者0.36(p=0.01)。
  • 病程每增加1年,最终DAS28(CRP)降低0.02(p<0.001)。
  • 基线DAS28(CRP)>5.1者最终DAS28(CRP)降低0.21(p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify patient characteristics associated with responsiveness to tumour necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA). MATERIALS AND METHODS: Individual patient data from 29 randomised controlled trials (RCTs) evaluating the efficacy of a TNFi versus placebo or conventional therapy were obtained. Response to treatment was assessed in subgroups according to the following baseline characteristics: smoking status, physical activity, sex, age, body mass index, autoantibody profile, disease duration, high initial disease activity defined by Disease Activity Score on 28 joints (DAS28)(C reactive protein (CRP)) >5.1. The primary outcome was the between-treatment group difference in DAS28(CRP) change from baseline to 6 months. The secondary endpoints were the between-treatment group difference in final DAS28(CRP) measured until 6 months and EULAR response criteria until 6 months. Data from each RCT were then pooled by the Mantel-Haenszel method using a random effects model. A linear metaregression was also carried out on two data-sharing platforms separately to support the results. RESULTS: Individual data of 11 617 patients from 29 RCTs were analysed. Until 6 months, a significantly higher EULAR non-response rate was observed in obese patients (OR 0.52 vs 0.36 for non-obese, p=0.01). A multivariable regression model performed on 7457 patients indicated that patients treated by TNFi had a final DAS28(CRP) decreased by 0.02 for each year of disease duration (p<0.001), and a 0.21 decreased for patients with a baseline DAS28(CRP) >5.1 (p<0.001). CONCLUSIONS: In RA, patients who are more responsive to TNFi are those who are non-obese, have a long disease duration and have a high initial disease activity.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Law-Wan J, Sparfel MA, Derolez S, et al. Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials. RMD Open. 2021. PMID: 34789535. doi:10.1136/rmdopen-2021-001882

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。